Profile of temsirolimus in the treatment of advanced renal cell carcinoma.
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
Department of Urology, University of Munich, Klinikum Grosshadern, Germany.
Michael
M
Staehler
Nicolas
N
Haseke
Wael
W
Khoder
Christian G
CG
Stief